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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYThe application of stem-cell-based therapies in regenerativemedicine is hindered by the tumorigenic potential of residual human plurip-
otent stem cells. Previously, we identified a human pluripotent stem-cell-specific lectin probe, called rBC2LCN, by comprehensive gly-
come analysis using high-density lectin microarrays. Here we developed a recombinant lectin-toxin fusion protein of rBC2LCN with a
catalytic domain of Pseudomonas aeruginosa exotoxin A, termed rBC2LCN-PE23, which could be expressed as a soluble form from the
cytoplasm of Escherichia coli and purified to homogeneity by one-step affinity chromatography. rBC2LCN-PE23 bound to human plurip-
otent stem cells, followed by its internalization, allowing intracellular delivery of a cargo of cytotoxic protein. The addition of rBC2LCN-
PE23 to the culturemediumwas sufficient to completely eliminate human pluripotent stem cells. Thus, rBC2LCN-PE23 has the potential
to contribute to the safety of stem-cell-based therapies.INTRODUCTION
Human pluripotent stem cells (hPSCs), such as human em-
bryonic stem cells (hESCs) (Thomson et al., 1998) and hu-
man induced pluripotent stem cells (hiPSCs) (Takahashi
et al., 2007), offer immense potential as cell sources for
cell-based therapies because of their capacity for unlimited
self-renewal and pluripotent differentiation. In particular,
hiPSCs are creating great expectations not only for regener-
ative medicine, but also for disease modeling and drug
development, as they can be generated from various adult
somatic cells simply by introducing reprogramming fac-
tors. Enormous efforts have been undertaken to establish
hPSC-based therapies for a variety of degenerative diseases
(Garber, 2013). Recently, the first in-human clinical trial us-
ing hiPSC-derived retinal pigment epithelium was con-
ducted by RIKEN Center for Developmental Biology in
Kobe to treat the wet form of age-related macular degener-
ation (Kamao et al., 2014). However, although the clinical
and industrial application of hPSC-based cell therapy is
becoming an increasingly realistic prospect, a major safety
concern still exists, as residual hPSCs in differentiated cell
populations could form tumors in recipients (Ben-David
and Benvenisty, 2011; Goldring et al., 2011; Lee et al.,
2013a).
Over the past several years, the tumorigenicity risks of
hPSCs have been highlighted in a number of animal
studies (Hentze et al., 2009; Kawai et al., 2010; Lee et al.,
2009; Roy et al., 2006; Yamashita et al., 2011). As few as
100 hPSCs have been reported to be sufficient to produceStema teratoma (Gropp et al., 2012; Hentze et al., 2009). There-
fore, complete elimination of hPSCs from the final cell
products without compromising their viability, safety, effi-
cacy, and functional properties is a prerequisite for clinical
application of hPSC-based therapy. It is also important to
remove residual hPSCs fromhPSC-derived cells to establish
disease models. Several strategies to remove residual hPSCs
from differentiated cell cultures have been reported, in-
cluding the introduction of suicide genes into hPSCs
(Schuldiner et al., 2003), selective killing using cytotoxic
antibodies (Ben-David et al., 2013b; Choo et al., 2008;
Tan et al., 2009) and chemical inhibitors (Ben-David
et al., 2013a; Lee et al., 2013b; Richards et al., 2014; Vaz-
quez-Martin et al., 2012), cell sorting using hPSC-specific
antibodies (Ben-David et al., 2013b; Tang et al., 2011) and
lectins (Wang et al., 2011), and glucose deprivation in the
cell culture medium (Tohyama et al., 2013). However, all
of these methods have some limitations in terms of speci-
ficity, throughput, efficacy, and safety. The development
of alternative strategies based on different mechanisms
therefore is warranted.
Previously, we performed comprehensive glycome anal-
ysis of a large number of hPSCs (114 types of hiPSCs
and nine types of hESCs) using high-density lectin micro-
arrays. We found that a lectin designated rBC2LCN (re-
combinant N-terminal domain of BC2L-C lectin derived
from Burkholderia cenocepacia) binds to various types of
hiPSCs and hESCs, but not to differentiated somatic cells
(Tateno et al., 2011). rBC2LCN is a useful hPSC probe,
which strongly stains formaldehyde-fixed hPSCs at theCell Reports j Vol. 4 j 811–820 j May 12, 2015 j ª2015 The Authors 811
Figure 1. Production of rBC2LCN-PE23
(A) Domain structure of rBC2LCN-PE23. rBC2LCN-PE23 consists of
an N-terminal rBC2LCN (156 amino acid residues), ten amino acid
linker (GSG3)2, and a catalytic domain of Pseudomonas aeruginosa
exotoxin A (399–613 amino acid, 215 amino acid residues) carrying
a C-terminal 63His tag (HHHHHH) and KDEL sequence.
(B) SDS-PAGE of purified rBC2LCN and rBC2LCN-PE23. Four micro-
grams of purified rBC2LCN and rBC2LCN-PE23 in either the presence
or absence of 2-mercaptoethanol (2ME) was run on a 5%–20%
acrylamide gel and stained with Coomassie G-250.
See also Figure S1 and Table S1.cell membrane (Onuma et al., 2013). In addition, it allows
live staining of hPSCs after supplementation of the culture
medium, with no visible signs of toxicity. The staining is
specific to undifferentiated cells, and rapidly diminishes
upon their differentiation. Detailed specificity analysis re-
vealed that rBC2LCN binds to the defined glycan struc-
ture, Fuca1-2Galb1-3GlcNAc/GalNAc (Sula´k et al., 2010;
Tateno et al., 2011). Among the N- and O-glycans isolated
from 201B7 hiPSCs, a core2-type O-glycan, Fuca1-2Galb1-
3(Galb1-4GlcNAcb1-6)GalNAc, was found to contain the
above glycan structure (Hasehira et al., 2012). rBC2LCN
exhibited a significant affinity (Ka of 2.5 3 10
4 M1) to
this core2-type O-glycan, demonstrating that it is a glycan
ligand of rBC2LCN (Tateno et al., 2013). Furthermore, po-
docalyxin, a type1 transmembrane protein, was identified
as a predominant glycoprotein ligand of rBC2LCN (Tateno
et al., 2013). Podocalyxin is a hyperglycosylated sialomu-
cin containing a mucin domain with >100 putative O-
glycosylation sites, five potential N-linked glycosylation
sites, and three putative glycosaminoglycan sites (Kershaw
et al., 1997). Due to its heavily glycosylated nature, the812 Stem Cell Reports j Vol. 4 j 811–820 j May 12, 2015 j ª2015 The Authoapparent molecular weight of podocalyxin expressed on
hPSCs is >200 kDa, despite the calculated molecular
weight of 55 kDa (Tateno et al., 2013). Although the bind-
ing affinity of rBC2LCN to the core2-type O-glycan is rela-
tively low, that to 201B7 hiPSCs is as high as antibody
(Ka = 5 3 10
8 M1), presumably due to the high-density
display of the glycan ligand on hPSCs, the so-called
‘‘glycoside cluster effect’’ (Dam and Brewer, 2010; Dam
et al., 2009). Most recently, the hyperglycosylated podoca-
lyxin was found to be secreted into cell culture media. Tak-
ing advantage of this phenomenon, a noninvasive and
quantitative detection system of tumorigenic hPSCs in
transplanting cells using cell culture media was developed
(Tateno et al., 2014).
Based on these principles, we speculated that the use
of rBC2LCN as a cargo of cytotoxic agent would provide
an efficient strategy to eliminate hPSCs. Here we generated
a recombinant lectin-toxin fusion protein by fusing
rBC2LCN with 23 kDa of a catalytic domain of Pseudo-
monas aeruginosa exotoxin A (rBC2LCN-PE23) for the tar-
geted elimination of hPSCs. rBC2LCN-PE23 could be
produced as a soluble form in E. coli at 10 mg/l culture
and purified to homogeneity using one-step affinity chro-
matography. It showed similar glycan binding specificity
to rBC2LCN, and, when added to culture medium, bound
to hiPSCs and was internalized by the cells. hiPSCs as
well as hESCs were eliminated after 24 hr culture in
the presence of rBC2LCN-PE23, although no effect was
observed for retinoic acid (RA)-treated hiPSCs, human
dermal fibroblasts (hFibs), and human adipose-derived
mesenchymal stem cells (hADSCs). Thus, rBC2LCN-PE23
could be used as a reagent to remove tumorigenic hPSCs
from differentiated cell populations, lowering the risk of
teratoma formation by its installation into hPSC-based
regenerative medicine.RESULTS
Production of rBC2LCN-PE23
We have demonstrated previously, by comprehensive gly-
come analysis using high-density lectin microarrays, that
rBC2LCN binds specifically to hPSCs and not to somatic
cells (Tateno et al., 2011). rBC2LCN (156 amino acids)
was fused with a truncated form of catalytic domain of
P. aeruginosa exotoxin A (399–613 residues; 215 amino
acids) carrying a C-terminal 63His tag (HHHHHH) and
KDEL sequence via a ten amino acid linker (GSG3)2 (Fig-
ure 1A). The generated rBC2LCN-PE23 (396 amino acids)
was expressed in E. coli and purified by one-step affinity
chromatography using an L-fucose-Sepharose column.
The yield was 10 mg/l of bacterial culture. rBC2LCN-
PE23 gave a major band at the predicted molecular weightrs
Figure 2. Internalization of rBC2LCN and
rBC2LCN-PE23
The 201B7 hiPSCs were live-stained with
either 1 mg/ml FITC-labeled rBC2LCN, FITC-
labeled rBC2LCN-PE23, or FITC-labeled BSA
for 2 hr. After replacing the medium without
probes, the cells were cultured for 24 hr.
Representative data are shown from two
independent experiments. Scale bar, 50 mm.of 42 kDa on SDS-PAGE in either the presence or absence of
2-mercaptoethanol, whereas rBC2LCN gave a major band
at 16 kDa (Figure 1B). Similar to rBC2LCN, rBC2LCN-
PE23 was soluble and showed no tendency to aggregate,
at least up to 3 months.
Glycan-Binding Property of rBC2LCN-PE23
We analyzed the glycan-binding property of rBC2LCN-
PE23 compared to rBC2LCN by glycoconjugate microarray
(Tateno et al., 2008) and frontal affinity chromatography
(Tateno et al., 2007). Based on glycoconjugate microarray
analysis, rBC2LCN-PE23 exhibited a similar glycan-bind-
ing specificity to that of rBC2LCN; both bound to Fuca1-
2Galb1-3GlcNAc/GalNAc-containing glycans, such as
Fuca1-2Galb1-3GlcNAc (H type1), Fuca1-2Galb1-3GalNAc
(H type3), and Fuca1-2Galb1-3(Fuca1-4)GlcNAc (Leb)
(Figure S1; Table S1). The dissociation constants (Kd) of
rBC2LCN and rBC2LCN-PE23 with H type1-para-nitrophe-
nol (pNP) and H type3-pNP were then determined by
frontal affinity chromatography (Tateno et al., 2007).
rBC2LCN-PE23 bound to H type1-pNP and H type3-pNPStemwith Kd of 9.9 and 32.3 mM, respectively, similar to
the dissociation constants of rBC2LCN to H type1-pNP
(8.3 mM) and H type3-pNP (25.4 mM). These results demon-
strate that rBC2LCN-PE23 exhibits glycan-binding proper-
ties similar to rBC2LCN.
rBC2LCN-PE23 Is Internalized by hiPSCs
We then examined whether rBC2LCN-PE23 binds to and is
internalized by hiPSCs. FITC-labeled rBC2LCN or FITC-
labeled rBC2LCN-PE23 (10 mg/ml) was added to the me-
dium of 201B7 hiPSC cultures, which were incubated for
2 hr. As shown in Figure 2, FITC-rBC2LCN stained the
cell membrane, whereas the cell membrane was only
weakly stained with FITC-rBC2LCN-PE23 and most stain-
ing was already observed inside the cells. After replacing
the medium without probes, the cells were cultured for a
further 24 hr, after which punctate staining was clearly
observed for both FITC-rBC2LCN and FITC-rBC2LCN-
PE23, indicating that they were internalized by the cells.
This observation strongly suggests that rBC2LCN could
be used to deliver cytotoxic agents inside hPSCs.Cell Reports j Vol. 4 j 811–820 j May 12, 2015 j ª2015 The Authors 813
Figure 3. Effect of rBC2LCN-PE23 on the
Cell Viability of hiPSCs
The 201B7 hiPSCs were cultured in mTeSR1
containing 0, 1, 2, 5, or 10 mg/ml rBC2LCN-
PE23. After 24 hr, the cells were stained and
observed by fluorescence microscopy. Live
cells stained cytoplasmic green fluores-
cence and dying or dead cells stained nu-
clear red fluorescence. Scale bar, 100 mm.
See also Figures S2 and S3.Cytotoxic Effect of rBC2LCN-PE23 on hPSCs
Having demonstrated that rBC2LCN-PE23 is internalized
by cells, we next examined whether it could induce cell
death of hPSCs. 201B7 hiPSCs were cultured in the pres-
ence (1, 2, 5, and 10 mg/ml) or absence of rBC2LCN-PE23
(Figure 3). After 24 hr, the cells were stained using a live/
dead cell imaging kit and observed under the microscope.
With this reagent, live cells are stained with cyto-
plasmic green fluorescence, and dying and dead cells are
stained with nuclear red fluorescence. In the absence of
rBC2LCN-PE23, the green fluorescence-positive live cells
proliferated normally and only a small number of dead
cells stained red, demonstrating that most of the cells
were viable. However, the number of green fluorescence-
positive 201B7 hiPSCs decreased as the concentration of
rBC2LCN-PE23 was increased. The green fluorescence-pos-814 Stem Cell Reports j Vol. 4 j 811–820 j May 12, 2015 j ª2015 The Authoitive 201B7 hiPSCs disappeared when the cells were
cultured in the presence of 10 mg/ml rBC2LCN-PE23 for
24 hr. Most of the dying or dead cells had detached from
the cell culture flasks and were floating in the medium.
The effect of rBC2LCN-PE23 also was quantified by
measuring the metabolic activity of living cells. As shown
in Figure 4, 201B7 hiPSCs were completely eliminated by
24 hr treatment with 10 mg/ml rBC2LCN-PE23. Similar re-
sults were obtained for 253G1 hiPSCs (Figures 4 and S2)
and H1 hESCs (Figures 4 and S3). Taken together, these
findings demonstrate that rBC2LCN-PE23 exerts a robust
cytotoxic effect on hPSCs.
Effect of rBC2LCN-PE23 on Differentiated Cells
We then examined the sensitivity of 201B7 hiPSCs
in response to rBC2LCN-PE23 after differentiation forrs
Figure 4. Quantitative Effect of
rBC2LCN-PE23 on the Cell Viability
Cells were cultured in either the presence or
absence of rBC2LCN-PE23 (0.1, 1, 10, and
100 mg/ml) to determine its cytotoxicity.
After 24 hr, the medium was replaced with
fresh medium supplemented with 20 ml CCK-
8 solution, and the absorbance at 450 nm
was measured after a further 4-hr incuba-
tion. Viability (%) was calculated from the
absorbance at 450 nm of treated cells rela-
tive to untreated cells. Data are shown as
mean ± SD of triplicates. RA, without RA
treatment; RA+, with RA treatment.10 days with RA (Figure 5). Most of RA-treated 201B7
hiPSCs proliferated normally and stained with green
fluorescence, indicative of viable cells, with only a small
number of cells staining red, even after 24 hr treatment
with 10 mg/ml rBC2LCN-PE23 (Figure 5, top). No effect
of rBC2LCN-PE23 on the viability of RA-treated 201B7
hiPSCs was observed at concentrations up to 100 mg/ml
(Figure 4).
We also analyzed the effect of rBC2LCN-PE23 on the
viability of hFibs and hADSCs. Both hFibs and hADSCs
were stained with green fluorescence, but not red fluores-
cence, even after 24 hr treatment with 10 mg/ml
rBC2LCN-PE23 (Figure 5, middle and bottom), and sub-
stantially no quantitative effect on viability was observed
(Figure 4). These results demonstrate that rBC2LCN-PE23
exerts a negligible cytotoxic effect on differentiated
cells, such as RA-differentiated hiPSCs, hADSCs, and
hFibs.
Selective Elimination of hiPSCs in a Mixed Cell
Population
A varying number of 201B7 hiPSCs cultured on 12-well
plates were labeled with CellTracker Green 5-chlorome-
thylfluorescein diacetate (CMFDA). After removing resid-
ual fluorescence, fluorescently labeled 201B7 hiPSCs
were co-cultured with hFibs in either the presence or
absence of 10 mg/ml rBC2LCN-PE23. After 40 hr, cells
were recovered and analyzed by flow cytometry (Figure 6).
In the absence of rBC2LCN-PE23, fluorescently labeled
201B7 hiPSCs and unlabeled hFibs were detected in
different ratios (31.6%–1.1% of 201B7 hiPSCs) (Figure 6,
top). In the presence of rBC2LCN-PE23, however, fluores-
cently labeled 201B7 hiPSCs almost completely disap-
peared (Figure 6, bottom). These results demonstrate
that rBC2LCN-PE23 can selectively eliminate hiPSCsStemeven in a mixed cell population with differentiated cells
at different ratios.DISCUSSION
hPSCs are a leading candidate as a source of cells for regen-
erative medicine due to their capacity for self-renewal and
pluripotency. Despite their therapeutic promise, a crucial
hurdle for the clinical implementation of hPSC therapies
is their tumorigenic potential. In this regard, various
strategies to eliminate hPSCs have been reported. One of
the major solutions involves antibody-based cell sorting.
However, processing of cells in this way is time-con-
suming, expensive, and could affect cell viability. In addi-
tion, this method is not directly applicable to two-/three-
dimensional cell cultures, such as cell sheets and tissues,
requiring single-cell preparation prior to separation.
Another popular solution is to use chemical inhibitors to
induce the selective cell death of tumorigenic hPSCs.
Given that chemical inhibitors are structurally defined,
can be stably supplied in large amounts, and show no/
minimal antigenicity, they are strong candidates to elimi-
nate tumorigenic hPSCs. However, one of the major
concerns with using small compounds is selectivity, i.e.,
possibility of side effect, which could affect the viability
of differentiated cells and cause adverse effects, as differen-
tiated cells share essentially the same metabolic system as
hPSCs.
One of the key findings of this study is that rBC2LCN is
internalized by hiPSCs. Taking advantage of this phenom-
enon, rBC2LCN was used as a cargo transporter to deliver
P. aeruginosa exotoxin A, which inactivates protein synthe-
sis. P. aeruginosa exotoxin A is synthesized as a single 638
residue polypeptide that is processed by the removal ofCell Reports j Vol. 4 j 811–820 j May 12, 2015 j ª2015 The Authors 815
Figure 5. Effect of rBC2LCN-PE23 on the
Cell Viability of Differentiated Cells
The 201B7 hiPSCs were cultured in mTeSR1
containing 10 mM RA for 10 days. hFibs and
hADSCs were cultured in mTeSR1 containing
10 mg/ml rBC2LCN-PE23. After 24 hr, cells
were stained and observed by fluorescence
microscopy. Live cells stained cytoplasmic
green fluorescence and dying or dead
cells stained nuclear red fluorescence.
Representative data are shown from at least
three independent experiments. Scale bar,
100 mm.25 N-terminal residues before secretion as the 613 residue
native toxin (Weldon and Pastan, 2011). It consists of
three major structural domains. The N-terminal domain I
is a receptor-binding domain, which is divided into two
non-sequential domains, domain Ia (1–252 residues) and
domain Ib (365–404 residues). Domain II (253–364 resi-
dues) has been proposed to be involved in toxin transloca-
tion and intracellular trafficking. Domain III (395–613
residues) is a catalytic domain, which catalyzes the in-
activation of eukaryotic translation elongation factor 2
(eEF2), an essential factor for protein synthesis, by transfer-
ring an ADP-ribosyl group from NAD+ to the diphthamide
residue (Weldon and Pastan, 2011). When fused with
antibodies, P. aeruginosa exotoxin A has been used to
create immunotoxins for the treatment of B cell malig-
nancies, mesothelioma, lung cancer, and brain tumors,
some of which have reached clinical trials (Weldon and
Pastan, 2011). The most commonly used fragment of
P. aeruginosa exotoxin A is a 38-kDa domain known as
PE38, containing a deletion of the majority of domain Ia
(D1–250 residues) and a portion of domain Ib (D365–380
residues) from the native form.
In this study, we fused 23 kDa of the catalytic domain
(399–613 residues), which may be the smallest fragment
of P. aeruginosa exotoxin A ever reported. The resulting re-
combinant cytotoxic lectin, rBC2LCN-PE23, could be ex-
pressed as a soluble form from the cytoplasm of E. coli
and purified to homogeneity by one-step affinity chroma-
tography at a relatively high yield (10 mg/l) sufficient
for the industrial use. In addition, rBC2LCN-PE23 ex-
hibited the same glycan-binding property as the native816 Stem Cell Reports j Vol. 4 j 811–820 j May 12, 2015 j ª2015 The AuthorBC2LCN. These results suggest that fusion with the cata-
lytic domain of P. aeruginosa exotoxin A at the C terminus
of rBC2LCN via an amino acid linker resulted in no/mini-
mal effect on the native structure of the latter, which forms
a homotrimer (Sula´k et al., 2010).
Although the fate of rBC2LCN-PE23 after internalization
has not been known, the chimeric protein is thought to
basically undergo an intoxication pathway similar to that
of P. aeruginosa exotoxin A (Weldon and Pastan, 2011). Af-
ter internalization, P. aeruginosa exotoxin A is cleaved at a
site in domain II by the endoprotease furin. In the Golgi,
P. aeruginosa exotoxin A encounters KDEL receptors that
transport the toxin to the ER. In the ER, the disulfide
bond is reduced and the C-terminal domain containing
the catalytic domain (domains II, Ib, and III) is released
into the cytosol. In the cytosol, the C-terminal domain
transfers an ADP-ribosyl group from NAD+ to the diphta-
mide residue of eEF2. This halts protein synthesis and leads
to apoptotic cell death. We are now studying in detail the
intracellular trafficking of rBC2LCN-PE23 using fluores-
cence microscopy and electron microscopy.
The addition of only 10 mg/ml rBC2LCN-PE23 to the cul-
turemediumwas sufficient to completely eliminate hiPSCs
after 24 hr, even in a mixed cell population. The dispersion
of colonies was not a prerequisite to induce cell death of
hiPSCs, demonstrating the high permeation ability of the
developed reagent. rBC2LCN-PE23 was also effective in
the case of hESCs, as rBC2LCN bound to all the types of
hESCs (KhES-1/2/3, H1/7) tested (Onuma et al., 2013; Ta-
teno et al., 2011). No effect was observed for RA-treated
hiPSCs, hFibs, and ADSCs, in agreement with a previousrs
Figure 6. Selective Killing of hiPSCs by rBC2LCN-PE23 in a Mixed Cell Population
Varying numbers of 201B7 hiPSCs were cultured and fluorescently labeled with 20 mM CellTracker Green CMFDA. After washing to remove
residual fluorescence, hFibs were mixed and co-cultured in either the presence (bottom) or absence (top) of 10 mg/ml rBC2LCN-PE23. After
40 hr, flow cytometry data were acquired.report that rBC2LCN shows no binding to differentiated
cells (Onuma et al., 2013; Tateno et al., 2011).
One possible concern could be the toxicity of residual
rBC2LCN-PE23 when transplanting cells, although this
could be washed away easily. Even if residual rBC2LCN-
PE23 exists, there should be no effect on differentiated
cells, since rBC2LCN-PE23 cannot bind to and be internal-
ized by differentiated cells. Outside of the cells, P. aeruginosa
exotoxin A exhibits no toxicity predicted from the intoxi-
cation pathway of the toxin.
The formation of neutralizing antibodies is a common
occurrence when foreign proteins are used as therapeutic
agents in humans. Given that rBC2LCN-PE23 containing
rBC2LCN and the catalytic domain of P. aeruginosa
exotoxin A is bacterial in origin, it is more likely that an im-
mune responsemight be generated if rBC2LCN-PE23 is car-
ried into humans. In this regard, the generation of less
immunogenic rBC2LCN-PE23 might be important, and
identifying and eliminating B cell and T cell epitopes
from its sequence (King et al., 2014) should be considered.
As described herein, rBC2LCN-PE23 could be stably sup-
plied and is cost-effective, and should be applicable to
various experiments requiring the elimination of hPSCs,
including the generation of hPSC-derived cells for drug
screening as well as therapy. For application of rBC2LCN-
PE23 to hPSC-based therapy, an appropriate protocol
would need to be developed in each clinical setting in
terms of standard operating procedure (SOP). hiPSC-
derived cardiomyocytes require approximately 108–109
cells for implantation to produce cardiac improvements
(Kawamura et al., 2012, 2013). In this case, even 1% of
hiPSCs corresponds to 106–107 cells, which is far more
than enough for teratoma formation (Gropp et al., 2012;StemHentze et al., 2009), which may cause life-threatening
events such as fatal arrhythmias, cardiac tamponade, and
heart failure (Yoshida and Yamanaka, 2010). Therefore,
it is mandatory to eliminate the risk of teratoma forma-
tion to realize the safety and efficacy of hiPSC-derived
cardiomyocytes,EXPERIMENTAL PROCEDURES
Construction, Expression, and Purification of
rBC2LCN-PE23
An N-terminal ten amino acid linker (GSG3)2, the truncated form
of the catalytic domain of P. aeruginosa exotoxin A (399–613
amino acid, 23 kDa), and a C-terminal 63His tag (PPHHHHHH)
followed by Lys-Asp-Glu-Leu (KDEL) was inserted via NheI and
XhoI into an expression vector of pET27b containing an N-termi-
nal domain (1–156 amino acid) of BC2L-C identified from Bur-
kholderia cenocepacia (rBC2LCN). The total number of amino acids
was 396 and the calculated average molecular weight was 41,673
Da. The generated rBC2LCN-toxin fusion protein was designated
as rBC2LCN-PE23.
The expression plasmid of rBC2LCN-PE23 was transformed into
E. coli BL21 CodonPlus (DE3)-RIL. The transformed E. coli was
cultured in LB medium containing 10 mg/ml kanamycin at 37C
until the OD600 reached 0.4. Expression of rBC2LCN-PE23 was
induced by the addition of 1 mM IPTG at 20C for 24 hr. The
following procedures were performed at 4C. The E. coli cells
were harvested by centrifugation at 4,4503 g for 30min and lyzed
in PBSET (6 mM Na2HPO4・12H2O, 1.4 mM KH2PO4, 140 mM
NaCl [pH 7.0], 1 mM EDTA, and 0.1% Triton X-100) containing
protease inhibitor cocktail (Nacalai tesque) by sonication. After
centrifugation at 24,9103 g for 30min, supernatants were applied
onto L-fucose-Sepharose and the bound rBC2LCN-PE23was eluted
with 0.2 M L-fucose in PBSE (6 mM Na2HPO4・12H2O, 1.4 mMCell Reports j Vol. 4 j 811–820 j May 12, 2015 j ª2015 The Authors 817
KH2PO4, 140 mM NaCl [pH 7.0], and 1 mM EDTA). The purified
rBC2LCN-PE23 was dialyzed against PBS. The protein concentra-
tion was measured by BCA protein assay (Thermo Scientific) and
the purity was analyzed by electrophoresis using 17% XV pantera
MP Gel (DRC).
SDS-PAGE
Fourmicrograms of purified rBC2LCNor rBC2LCN-PE23 was incu-
bated at 95C for 5 min in either the presence or absence of 2-mer-
captoethanol and run on a 5%–20% polyacrylamide gel (DRC).
The gel was then stained with Bio-Safe Coomassie G-250 Stain
(Bio-Rad).
Frontal Affinity Chromatography
The principle and protocol for frontal affinity chromatography
have been described previously (Nakamura et al., 2005; Tateno
et al., 2007).
Cell Culture
The 201B7 and 253G1 hiPSCs were cultured in mTeSR1 (STEM-
CELL Technologies) on cell culture plates coated with Matrigel
(BD Biosciences) (Nakagawa et al., 2008; Takahashi et al., 2007).
The hESC line H1 was cultured in mTeSR1 according to theWiCell
Feeder Independent Pluripotent Stem Cell Protocols provided by
the WiCell Research Institute (http://www.wicell.org). 201B7 and
H1 hESCs were differentiated by culturing them in mTeSR1 con-
taining 10 mM RA for 10 days. hFibs and hADSCs were cultured
in MesenPRO RS medium. Cells were counted with a hemocytom-
eter, a Vi-CELL Cell Viability Analyzer (Beckman Coulter Geno-
mics), or a TC20 Automated Cell Counter (Bio-Rad). hiPSCs and
hESCs used in this study were confirmed to have the ability to
form teratoma and be positive for both anti-SSEA4 and rBC2LCN
(Tateno et al., 2014).
Internalization Assay
201B7 hiPSCs were cultured in mTeSR1 on four-well coverglass
chambers (AGC Techno Glass) coated with Matrigel. Hoe-
chist33342 (Dojindo) (0.5 mg/ml) and 1 mg/ml of either FITC-
labeled rBC2LCN, FITC-labeled rBC2LCN-PE23, or FITC-labeled
BSA were added to the culture medium for 2 hr. After replacing
the medium without probes, the cells were observed under a Fluo-
View FV1000 confocal laser-scanning microscope (Olympus).
Cell Viability Assay
The cytotoxic effect of rBC2LCN-PE23 was analyzed using a
LIVE/DEAD Cell Imaging Kit (Molecular Probes). Cells were
cultured in mTeSR1 on 6- or 12-well plates coated with Matrigel
in the presence or absence of rBC2LCN-PE23 (1 and 10 mg/ml).
After 24 hr, they were stained with Live Green (A) and Dead
Red (B) reagents, according to the manufacturer’s instructions,
and observed under an Axio Vert.A1 (Carl Zeiss) or BZ-9000 fluo-
rescence microscope.
The cytotoxic effect of rBC2LCN-PE23 also was analyzed using a
Cell Counting Kit-8 (Dojindo). Cells were cultured in 500 ml
mTeSR1 on 24-well plates coated with Matrigel in the presence
or absence of rBC2LCN-PE23 (0.1, 1, 10, and 100 mg/ml). After818 Stem Cell Reports j Vol. 4 j 811–820 j May 12, 2015 j ª2015 The Autho24 hr, the culture medium was replaced with 200 ml fresh medium
and 20 ml CCK-8 solution, and, after a further 4-hr incubation in a
CO2 incubator, the absorbance at 450 nm was measured.
Flow Cytometry
Varying numbers of 201B7 hiPSCs were cultured inmTeSR1 on 12-
well plates coated with Matrigel. Adherent 201B7 hiPSCs were flu-
orescently labeled with 20 mM CellTracker Green CMFDA (Life
Technologies) at 37C for 45min. After replacing themedium, cells
were further cultured at 37C for 30 min. Unlabeled hFibs were
seeded and co-cultured in either the presence or absence of
10 mg/ml rBC2LCN-PE23. After 40 hr, cells were recovered and
centrifuged at 5,000 rpm for 1 min. After removing the superna-
tant, the cells were suspended in 1 ml PBS containing 1% BSA.
Finally, flow cytometry data were acquired on a FACSCanto-II cy-
tometer (BD Biosciences) and analyzed using FlowJo software
(Tree Star).
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